Although Alembic Pharma has witnessed P/E expansion from ~8-10x levels to 10-13x levels, we see enough room for further re-rating on the stock as its US pipeline unfolds. The stock still trades at an attractive valuation of 14.9x FY15E EPS and 11.1x FY16E EPS. We value Alembic Pharma at 15x FY16E EPS of Rs 26.1 and recommend BUY with a TP of Rs 392
READ MORE »Posts tagged Alembic Pharma
Alembic Pharma Research Report By Motilal Oswal
Improving business profile; re- rating candidate: The business mix at Alembic Pharma is likely to improve further, with higher contribution from US generics and specialty therapies in India, while low-margin APIs and acute therapies may continue to face slowdown. We expected transition to result in 280bp EBITDA margin expansion and 35% earnings CAGR over FY14E-16E. […]
READ MORE »